239 related articles for article (PubMed ID: 28396341)
1. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
2. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
[TBL] [Abstract][Full Text] [Related]
3. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
[TBL] [Abstract][Full Text] [Related]
5. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
6. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
7. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
8. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA
Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587
[TBL] [Abstract][Full Text] [Related]
9. Oral Pharmacological Activation of Hypothalamic Guanylate Cyclase 2C Receptor Stimulates Brown Fat Thermogenesis to Reduce Body Weight.
Folgueira C; Torres-Leal FL; Beiroa D; Pena-León V; Da Silva Lima N; Milbank E; Senra A; Al-Massadi O; López M; Diéguez C; Seoane LM; Nogueiras R
Neuroendocrinology; 2020; 110(11-12):1042-1054. PubMed ID: 31945763
[TBL] [Abstract][Full Text] [Related]
10. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
11. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
12. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
[TBL] [Abstract][Full Text] [Related]
13. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
[TBL] [Abstract][Full Text] [Related]
14. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
[TBL] [Abstract][Full Text] [Related]
15. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity
Boulete IM; Thadi A; Beaufrand C; Patwa V; Joshi A; Foss JA; Eddy EP; Eutamene H; Palejwala VA; Theodorou V; Shailubhai K
World J Gastroenterol; 2018 May; 24(17):1888-1900. PubMed ID: 29740204
[TBL] [Abstract][Full Text] [Related]
16. Linaclotide for the treatment of chronic constipation.
Bassotti G; Usai-Satta P; Bellini M
Expert Opin Pharmacother; 2018 Aug; 19(11):1261-1266. PubMed ID: 29985664
[TBL] [Abstract][Full Text] [Related]
17. Intestinal neuropod cell GUCY2C regulates visceral pain.
Barton JR; Londregan AK; Alexander TD; Entezari AA; Bar-Ad S; Cheng L; Lepore AC; Snook AE; Covarrubias M; Waldman SA
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36548082
[TBL] [Abstract][Full Text] [Related]
18. Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation.
Waldman SA; Tenenbaum R; Foehl HC; Winkle P; Griffin P
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00016. PubMed ID: 31318728
[TBL] [Abstract][Full Text] [Related]
19. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice.
Li P; Lin JE; Snook AE; Waldman SA
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28895923
[TBL] [Abstract][Full Text] [Related]
20. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]